ArticleSurgical endoscopy2026
Robotic-assisted cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a minimally invasive approach for peritoneal carcinomatosis in patients with low burden disease.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeritoneal carcinomatosis (PC) presents a significant challenge and is often associated with poor prognosis. Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) stands as a well-established treatment modality for various forms of PC. The peritoneal cancer index (PCI) is used to assess the intraperitoneal disease burden, with evidence suggesting a linear correlation with overall survival, particularly in colorectal cancers with peritoneal metastasis. Similarly, completeness of cytoreduction (CC) is assessed post-resection to quantitatively measure residual disease in the abdomen. There has been a growing trend toward minimally invasive CRS-HIPEC, though achieving an accepted CC using this approach has been less frequently reported. This article describes the experience at our institution after ten cases of robotic-assisted CRS-HIPEC. MATERIALS AND
methodsData from the ten consecutive R-CRS-HIPEC were retrospectively collected. Comprehensive preoperative imaging and multidisciplinary team deliberations were conducted for case selection. Mini-invasive robotic CRS-HIPEC was considered only for patients exhibiting a limited amount of PC, as evidenced by prior laparoscopy (PCI < 10). To compare surgical outcomes with a homogeneous population of patients undergoing open CRS and HIPEC, 18 consecutive patients treated in the pre-robotic era were retrospectively included, all with PCI < 10 and histology consistent with appendiceal-origin neoplasms.
resultsNo perioperative complications were noted, and all patients were discharged within seven days of the operation.
conclusionsRobotic-assisted CRS-HIPEC for appendiceal mucinous neoplasms in highly selected patients is a safe and feasible procedure. A low intraperitoneal tumor burden in patients with intraperitoneal mucinous neoplasms emerges as a mandatory prerequisite to approach CRS-HIPEC with a robotic approach. We endorse ongoing investigation and future prospective clinical trials employing this technique.
Indexed as
Identifiers
42265291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.